NASDAQ: LVTXLava Therapeutics Nv Stock
$1.64+0.02 (+1.23%)
Updated Mar 29, 2023
LVTX Price
$1.64
Fair Value Price
$4.02
Market Cap
$43.11M
52 Week Low
$1.56
52 Week High
$7.38
P/E
-1.19x
P/B
0.46x
P/S
6.77x
PEG
N/A
Dividend Yield
N/A
Revenue
$18.31M
Earnings
-$28.69M
Gross Margin
100%
Operating Margin
-178.36%
Profit Margin
-182%
Debt to Equity
0.62
Operating Cash Flow
-$39M
Beta
0.1
Next Earnings
May 15, 2023
Ex-Dividend
N/A
Next Dividend
N/A
LVTX Overview
LAVA Therapeutics N.V. offers Gammabody platform, a portfolio of novel bispecific antibodies that engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. The company's lead clinical-stage candidates are LAVA-051, in Phase 1/2a clinical trials for blood cancers (chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia), and LAVA-1207, in Phase 1/2a clinical trials for metastatic castration-resistant prostate cancer. LAVA Therapeutics was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LVTX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LVTX ($1.64) is undervalued by 59.23% relative to our estimate of its Fair Value price of $4.02 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
LVTX ($1.64) is significantly undervalued by 59.23% relative to our estimate of its Fair Value price of $4.02 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
LVTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more LVTX due diligence checks available for Premium users.
Be the first to know about important LVTX news, forecast changes, insider trades & much more!
LVTX News
Valuation
LVTX fair value
Fair Value of LVTX stock based on Discounted Cash Flow (DCF)
Price
$1.64
Fair Value
$4.02
Undervalued by
59.23%
LVTX ($1.64) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
LVTX ($1.64) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
LVTX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
LVTX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.19x
Industry
18.17x
Market
21.81x
LVTX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.46x
Industry
4.92x
LVTX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LVTX's financial health
Profit margin
Revenue
$15.3M
Net Income
$997.0k
Profit Margin
6.5%
LVTX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
LVTX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$149.9M
Liabilities
$57.2M
Debt to equity
0.62
LVTX's short-term assets ($149.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LVTX's short-term assets ($149.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LVTX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$14.3M
Investing
$6.6M
Financing
-$7.0k
LVTX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LVTX vs Biotech Stocks
Lava Therapeutics Nv Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.